ClinicalTrials.gg
CompletedNCT00381381Updated Jan 4, 2022Results posted

The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease

A Phase 4 interventional study of Donepezil in Alzheimer's Disease, sponsored by Eisai Korea Inc.. Completed at 15 sites in Korea, Republic of. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-01-04.

Sponsored by Eisai Korea Inc. (part of Eisai Co., Ltd.) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2006, registered Sep 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
199
Allocation
Non-randomized
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
14th of 58
199 · median 79
Started
2006
with 3 others
Phase 4
20 of 60
none open now
Registered
12th of 60
by date
Lead sponsor
4 of 60
Eisai Korea Inc.

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 14th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2006, is one of 20 in phase 4, and was the 12th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

This study attempts to differentiate the clinical responses of Choline Acetyltransferase and Apolipoprotein Epsilon gene polymorphism to donepezil in Alzheimer's Disease patients.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's disease
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 60 - 90 years old.
  2. CDR: 0.5 - 2.0.
  3. Patients who do not have severe depressive symptoms that affect cognition on depression scale of CERAD-K(C), GDS-K: 19 and below.
  4. Modified Hachinski Ischemic Score (Rosen, et. al., 1979): 3 and below.
  5. NINCDS-ADRDA criteria: Probable AD.

Exclusion criteria

Exclusion criteria:

  1. Patients who have delusions and other conscious dysfunction.
  2. Patients who have neurologic diseases such as Parkinson's disease, stroke, tumor, normal pressure hydrocephalus, etc., on history and neurologic examination.
  3. Patients who have history of infectious and inflammatory brain disease owing to virus, fungus and syphilis.
  4. Patients with severe cerebrovascular pathology.
  5. Patients who have present history of major psychological diseases such as depression and mania according to criteria.
  6. Patients who have history of alcoholism or drug addiction.
  7. Patients who have severe depressive symptoms that affect cognition on depression scale of CERAD-K.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    1

    Drug: Donepezil

Interventions

  • 2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.

    Also known as: Aricept

06

What researchers measure

Primary outcomes

  1. CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease)

    CERAD-K includes: Verbal Fluency-number of kinds of animal patients listed per minute, ranges from 0, no maximum point fixed.Boston Naming Test is naming objects (0-15). Mini-Mental State Examination in the Korean version of CERAD Assessment Packet (0-30). Word List Memory (0-30). Construction Praxis is from 0-11. Word List Recall and Word List Recognition ranges from 0-10.Construction Recall (0-11).

    Time frame: 26 weeks

  2. CERAD-K

    CERAD-K includes: Trail making test A and B is scored by the time spent to link randomly arranged numbers and alphabets in correct order. Except Trail making test A and B, higher score presents better condition.

    Time frame: 26 weeks

Secondary outcomes

  1. Neuropsychiatry Inventory (NPI)

    NPI score after treatment. NPI includes 12 sections which are Delusions, Hallucinations, Agitation, Depression, Anxiety, Euphoria, Apathy, Disinhibition, Irritability, Aberrant motor behavior, Night-time behaviors and Appetite and eating disorders. The score of each section ranges from 0 to 12, and higher score means higher severity and frequency of the neuropsychiatric disturbances.

    Time frame: 26 weeks

  2. GDS-K (Geriatric Depression Scale-Korean) Score After Treatment

    GDS-K score after treatment. Geriatric Depression Scale is a basic screening measure for depression in older adults. It ranges from 0 to 30, and higher score represents more depressed.

    Time frame: 26 weeks

07

Results

Posted Jul 27, 2012

Participant flow

This study was recruited at 15 centers in Korea during the period of June 2006 to August 2008.

Participant flow — Overall Study
MilestoneDonepezil
Started199
Completed135
Not completed64
Withdrew: Adverse event3
Withdrew: Lost to follow-up52
Withdrew: Withdrawal by subject9

Outcome measures

PrimaryCERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease)

CERAD-K includes: Verbal Fluency-number of kinds of animal patients listed per minute, ranges from 0, no maximum point fixed.Boston Naming Test is naming objects (0-15). Mini-Mental State Examination in the Korean version of CERAD Assessment Packet (0-30). Word List Memory (0-30). Construction Praxis is from 0-11. Word List Recall and Word List Recognition ranges from 0-10.Construction Recall (0-11).

Time frame:
26 weeks
Reported as:
Mean · Units on Scale
CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease)
Units on ScaleDonepezil
Verbal Fluency8.28 ± 3.71
Boston Naming Test7.31 ± 3.25
MMSE-KC17.86 ± 5.25
Word List Memory10.62 ± 6.20
Construction Praxis7.61 ± 2.71
Word List Recall1.98 ± 1.99
Word List Recognition4.64 ± 3.24
Construction Recall2.11 ± 2.71
SecondaryNeuropsychiatry Inventory (NPI)

NPI score after treatment. NPI includes 12 sections which are Delusions, Hallucinations, Agitation, Depression, Anxiety, Euphoria, Apathy, Disinhibition, Irritability, Aberrant motor behavior, Night-time behaviors and Appetite and eating disorders. The score of each section ranges from 0 to 12, and higher score means higher severity and frequency of the neuropsychiatric disturbances.

Time frame:
26 weeks
Reported as:
Mean · Units on Scale
Neuropsychiatry Inventory (NPI)
Units on ScaleDonepezil
Delusions0.49 ± 1.85
Hallucinations0.12 ± 0.69
Agitation0.54 ± 1.56
Depression0.76 ± 1.82
Anxiety0.70 ± 2.10
Euphoria0.02 ± 0.19
Apathy1.44 ± 2.69
Disinhibition0.28 ± 1.19
Irritability0.67 ± 1.93
Aberrant motor behavior0.44 ± 1.71
Night-time behaviors0.40 ± 1.68
Appetite and eating disorders0.43 ± 1.46
SecondaryGDS-K (Geriatric Depression Scale-Korean) Score After Treatment

GDS-K score after treatment. Geriatric Depression Scale is a basic screening measure for depression in older adults. It ranges from 0 to 30, and higher score represents more depressed.

Time frame:
26 weeks
Reported as:
Mean · Units on Scale
GDS-K (Geriatric Depression Scale-Korean) Score After Treatment
Units on ScaleDonepezil
GDS-K (Geriatric Depression Scale-Korean) Score After Treatment11.69 ± 6.42
PrimaryCERAD-K

CERAD-K includes: Trail making test A and B is scored by the time spent to link randomly arranged numbers and alphabets in correct order. Except Trail making test A and B, higher score presents better condition.

Time frame:
26 weeks
Reported as:
Mean · Second
CERAD-K
SecondDonepezil
Trail making test A206.64 ± 126.94
Trail making test B290.88 ± 30.20

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil—4/199 (2%)30/199 (15.1%)
Most frequent serious events
Most frequent serious events
EventDonepezil
AnorexiaPsychiatric disorders1/199
General WeaknessGeneral disorders1/199
StrokeVascular disorders1/199
Ankle FractureMusculoskeletal and connective tissue disorders1/199
Malignancy Of Unknown OriginGeneral disorders1/199
Most frequent other events
Most frequent other events
EventDonepezil
AnorexiaPsychiatric disorders7/199
DizzinessNervous system disorders7/199
NauseaGastrointestinal disorders5/199
HeadacheNervous system disorders5/199
Abdominal DiscomfortGastrointestinal disorders4/199
WeaknessGeneral disorders3/199
VomitingGastrointestinal disorders2/199

Baseline characteristics

Age, Continuous
Age, Continuous(years)Donepezil
Mean74.6 ± 6.5
Sex: Female, Male
Sex: Female, Male(Participants)Donepezil
Female136
Male63
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Donepezil
American Indian or Alaska Native0
Asian199
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

15 sites
  • Seoul National University Bundang Hospital
    Bundang, Korea, Republic of
  • Hallym University Medical Center
    Changwon, Korea, Republic of
  • Kangwon National University Hospital
    Chuncheon, Korea, Republic of
  • Kunkuk University Chungju Hospital
    Chungju, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, Korea, Republic of
  • Gyeonggi Province Geriatric Hospital
    Gyeonggi, Korea, Republic of
  • Uijeongbu St. Mary's Hospital
    Gyeonggi, Korea, Republic of
  • Jeju National University Hospital
    Jeju, Korea, Republic of
  • Jeonju City Welfare Hospital
    Jeonju, Korea, Republic of
  • Gyeongsang National University Hospital
    Jinju, Korea, Republic of
  • Inje University Pusan Paik Hospital
    Pusan, Korea, Republic of
  • Kunkuk University Hospital
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2006 to primary completion in Aug 2008, 27 months.

Results were first posted in Jul 2012, 3 years 10 months after primary completion.

Of 41 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2006
First posted
Sep 27, 2006
StartActual
May 31, 2006
Primary completionActual
Aug 31, 2008
CompletionActual
Dec 31, 2008
Results first posted
Jul 27, 2012
Last update
Jan 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00381381
Lead sponsor
Eisai Korea Inc.
Responsible party
Sponsor
First posted
Sep 27, 2006
Start date
May 31, 2006
Primary completion
Aug 31, 2008
Completion
Dec 31, 2008
Results posted
Jul 27, 2012
Last update
Jan 4, 2022

Study contacts

Jihee Mun
study director · Eisai Korea Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion